Abstract
It has been reported that DOK3 protein negatively regulates LPS responses and endotoxin tolerance in mice. However, the role of DOK3 in the development of acute respiratory distress syndrome (ARDS) remains unknown. In this study, we showed that DOK3 is degraded in the lung tissues of LPS-induced ARDS. Through lentivirus transduction containing DOK3(K27R) via the intranasal route, we created a mice model, in which DOK3 maintains stable expression. We found that the forced DOK3 expression significantly attenuated LPS-induced pulmonary histological alterations, inflammatory cells infiltration, lung edema, as well as the generation of inflammatory cytokines TNFα, IL- 1β and IL-6 in BALF of LPS-induced ARDS mice. In addition, DOK3 expression apparently suppressed LPS-induced NF-κB and ERK activation. These data suggested that DOK3 expression negatively regulates the development of LPS-induced ARDS in mice.
Keywords: ARDS, DOK3, Lentivirus, LPS, Degradation, Expression.
Current Gene Therapy
Title:DOK3 Degradation is Required for the Development of LPS-induced ARDS in Mice
Volume: 16 Issue: 4
Author(s): Ning Liu, Xiaofeng Liu, Xiaoou Li, Kaifang Duan, Yuming Deng, Xiuyan Yu and Qisheng Peng
Affiliation:
Keywords: ARDS, DOK3, Lentivirus, LPS, Degradation, Expression.
Abstract: It has been reported that DOK3 protein negatively regulates LPS responses and endotoxin tolerance in mice. However, the role of DOK3 in the development of acute respiratory distress syndrome (ARDS) remains unknown. In this study, we showed that DOK3 is degraded in the lung tissues of LPS-induced ARDS. Through lentivirus transduction containing DOK3(K27R) via the intranasal route, we created a mice model, in which DOK3 maintains stable expression. We found that the forced DOK3 expression significantly attenuated LPS-induced pulmonary histological alterations, inflammatory cells infiltration, lung edema, as well as the generation of inflammatory cytokines TNFα, IL- 1β and IL-6 in BALF of LPS-induced ARDS mice. In addition, DOK3 expression apparently suppressed LPS-induced NF-κB and ERK activation. These data suggested that DOK3 expression negatively regulates the development of LPS-induced ARDS in mice.
Export Options
About this article
Cite this article as:
Liu Ning, Liu Xiaofeng, Li Xiaoou, Duan Kaifang, Deng Yuming, Yu Xiuyan and Peng Qisheng, DOK3 Degradation is Required for the Development of LPS-induced ARDS in Mice, Current Gene Therapy 2016; 16 (4) . https://dx.doi.org/10.2174/1566523216666161103142342
DOI https://dx.doi.org/10.2174/1566523216666161103142342 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene Therapy Approaches in an Autoimmune Demyelinating Disease: Multiple Sclerosis
Current Gene Therapy Molecular Cytogenetic Diagnosis and Somatic Genome Variations
Current Genomics Circulating Aminopeptidase Activities in Men and Women with Essential Hypertension
Current Medicinal Chemistry Stent Selection in Patients with Myocardial Infarction: Drug Eluting, Biodegradable Polymers or Bare Metal Stents?
Recent Patents on Cardiovascular Drug Discovery Platelets in Atherothrombosis: New and Evolving Roles
Current Pharmaceutical Design GABA<sub>B</sub> Agonists for the Treatment of Alcohol Use Disorder
Current Pharmaceutical Design PD-1/PD-Ls: A New Target for Regulating Immunopathogenesis in Central Nervous System Disorders
Current Drug Delivery Quinone Methide Bioactivation Pathway: Contribution to Toxicity and/or Cytoprotection?
Current Organic Chemistry A Role for the Adenosine ADORA2B Receptor in Midazolam Induced Cognitive Dysfunction
Current Pharmaceutical Design The Role of Cancer Biomarkers in HIV Infected Hosts
Current Medicinal Chemistry Treatment of Allergic Rhinitis in Children
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Novel Therapeutic Strategies for Fibrotic Lung Disease: A Review with a Focus on Epithelial-Mesenchymal Transition
Recent Patents on Inflammation & Allergy Drug Discovery Anaesthesia in Cancer Surgery: Can it Affect Cancer Survival?
Current Clinical Pharmacology Editorial [Hot Topic: Emerging Viruses: Advances and Challenges (Executive Editor: Thomas W. Geisbert)]
Current Molecular Medicine Evaluation of Serum Level of Carnitine in Children with Acute Pyelonephritis (APN) Compared to Healthy Children
Reviews on Recent Clinical Trials New Approaches to Structure-Based Discovery of Dengue Protease Inhibitors
Infectious Disorders - Drug Targets Steatohepatitis in HIV-Infected Subjects: Pathogenesis, Clinical Impact and Implications in Clinical Management
Current HIV Research IL-1β and IL-1Ra Variant Profiles in Turkish Patients with Diabetic Peripheral Neuropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Complement C4A and C4B Gene Copy Number Study in Alzheimer's Disease Patients
Current Alzheimer Research Editorial [Hot Topic: Pathophysiology and Current Therapeutics of Inflammatory Diseases (Guest Editor: Fadia R. Homaidan)]
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents